2008 Immunity Vaccines 
Pharmacy Times
JUNE 17, 2025
Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.
PharmaShots
APRIL 25, 2023
Founded Year: 2008 Total Employees: ~2110 Headquarters: Dublin, Ireland Market Cap: $1.7M Through its internal development, partnerships, and acquisitions, the company has put together four technology platforms that primarily focus on antibodies, T cells, innate immunity, and siRNAs. R&D Expenditure: $437.9M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
MARCH 9, 2023
In addition to serving as Associate Editor-in-Chief of the IEEE Open Access Journal of Circuits and Systems, she has been an Associate Editor of IEEE Transactions on Biomedical Circuits and Systems since 2008. Designation: Global Head Previous company: Merck Global Vaccines (2 yrs. LinkedIn Total experience: 26 yrs.
PharmaShots
JANUARY 31, 2023
The company’s product portfolio comprises two platforms: Virax Immune, a new-Covid-19 test detecting the T-Cell immune response to the SARS-Cov-2 virus and ViraxClear, a platform to sell a range of highly accurate diagnostic test kits and machines. Founded Year: 2008 No. Funding Value: $7.7M Founded Year: 2021 No.
pharmaphorum
DECEMBER 21, 2020
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.
Pharmaceutical Technology
FEBRUARY 20, 2023
You were the chief operating officer (COO) at Viroclinics-DDL before the acquisition, joining Viroclinics-DDL in 2008. The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020.
Pharmaceutical Technology
AUGUST 26, 2008
We are now one of the ten largest biopharma companies in the world with a rich armoury of new technology, comprising a full suite of technologies, small molecules, antibodies and vaccines to create new human medicines.” The DEEP study results, along with data from further analyses, are under review by a potential licensing partner.
Expert insights. Personalized for you.
26 
Let's personalize your content